Pegnivacogin
- Generic Name
- Pegnivacogin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H40N3O11P
- CAS Number
- 959716-28-0
- Unique Ingredient Identifier
- AYC3D1NPYB
- Indication
Investigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.
A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 640
- Registration Number
- NCT00932100
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
Phase 2
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2013-05-31
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00715455
- Locations
- 🇺🇸
Black Hills Clinical Research Center, Rapid City, South Dakota, United States
🇺🇸Henry Ford, Detroit, Michigan, United States
🇺🇸The Care Group, LLC, Indianapolis, Indiana, United States
Safety and Dosing Evaluation of REG1 Anticoagulation System
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 106
- Registration Number
- NCT00113997
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath